Want to see IN:SMSPHARMA full AI Analyst Report?
SMSPHARMA Stock Chart & Stats
₹380.80
₹10.80(2.83%)
At close: 4:00 PM EDT
₹380.80
₹10.80(2.83%)
Day’s Range― - ―
52-Week Range₹270.80 - ₹494.40
Previous CloseN/A
Volume99.05K
Average Volume (3M)52.60K
Market Cap
₹40.65B
Enterprise Value₹36.41B
Total Cash (Recent Filing)₹460.75M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)38.6
Beta1.40
Next Earnings
Nov 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.09%
Share Statistics
EPS (TTM)11.24
Shares Outstanding93,652,030
10 Day Avg. Volume13,282
30 Day Avg. Volume52,599
Financial Highlights & Ratios
PEG Ratio0.91
Price to Book (P/B)4.36
Price to Sales (P/S)3.87
P/FCF Ratio-37.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Profit And Revenue RecoveryThe return to solid profitability after the FY2023 loss, alongside continued revenue growth, indicates that the business has regained operating traction. If maintained, this recovery can strengthen reinvestment capacity and support earnings development over the next several quarters.
Improving Balance SheetDebt reduction combined with a larger equity base improves financial resilience and reduces balance-sheet pressure. This gives SMS Pharmaceuticals greater flexibility to manage business cycles and fund operations, even though the company still needs to convert earnings into stronger cash generation.
API Manufacturing PositionFocusing on active pharmaceutical ingredients and intermediates positions the company within an essential input segment of the drug industry. Serving both domestic and international markets provides a broad commercial base and supports repeat demand from formulation manufacturers.
Bears Say
Weak Free Cash FlowPersistent negative free cash flow shows that reported earnings are not consistently translating into cash after operating and investment needs. This can constrain internally funded expansion, increase reliance on financing, and weaken the durability of the recent earnings recovery.
Margin VolatilityThe sharp gross-margin decline demonstrates that profitability is sensitive to changes in the business cycle and operating economics. Such volatility makes future earnings less predictable and can reduce the benefit of revenue growth if margins fail to stabilize at stronger levels.
Uneven Earnings PowerThe transition from a loss year to recent profits is encouraging, but the uneven record indicates that earnings power has not yet been consistently established. A repeat downturn could pressure returns and diminish the balance-sheet improvement achieved during the recovery.
SMS Pharmaceuticals Limited News
SMSPHARMA FAQ
What was SMS Pharmaceuticals Limited’s price range in the past 12 months?
SMS Pharmaceuticals Limited lowest stock price was ₹270.80 and its highest was ₹494.40 in the past 12 months.
What is SMS Pharmaceuticals Limited’s market cap?
SMS Pharmaceuticals Limited’s market cap is ₹40.65B.
When is SMS Pharmaceuticals Limited’s upcoming earnings report date?
SMS Pharmaceuticals Limited’s upcoming earnings report date is Nov 06, 2026 which is in 14 days.
How were SMS Pharmaceuticals Limited’s earnings last quarter?
SMS Pharmaceuticals Limited released its earnings results on Jul 31, 2026. The company reported ₹2.233 earnings per share for the quarter.
Is SMS Pharmaceuticals Limited overvalued?
According to Wall Street analysts SMS Pharmaceuticals Limited’s price is currently Overvalued.
Does SMS Pharmaceuticals Limited pay dividends?
SMS Pharmaceuticals Limited pays a Annually dividend of ₹0.4 which represents an annual dividend yield of 0.09%. See more information on SMS Pharmaceuticals Limited dividends here
What is SMS Pharmaceuticals Limited’s EPS estimate?
SMS Pharmaceuticals Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does SMS Pharmaceuticals Limited have?
SMS Pharmaceuticals Limited has 93,652,030 shares outstanding.
What happened to SMS Pharmaceuticals Limited’s price movement after its last earnings report?
SMS Pharmaceuticals Limited reported an EPS of ₹2.233 in its last earnings report. Following the earnings report the stock price went up 0.121%.
Which hedge fund is a major shareholder of SMS Pharmaceuticals Limited?
Currently, no hedge funds are holding shares in IN:SMSPHARMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
SMS Pharmaceuticals Limited
SMS Pharmaceuticals Limited, an Indian company established in 1987 and based in Hyderabad, specializes in the production and distribution of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates. The firm offers a wide array of APIs targeting various therapeutic categories, including anti-ulcer, anti-fungal, anti-migraine, anti-diabetic, erectile dysfunction, antiemetic, antiepileptic, antipsychotic, anti-hypertensive, anti-anginal, anti-viral, urinary antispasmodic, and anti-retroviral applications. Furthermore, SMS Pharmaceuticals engages in contract research activities and exports its products globally.
Technical Analysis
Gland Pharma Ltd.
―
Kopran Limited
―
Marksans Pharma Limited
―
NGL Fine-Chem Ltd.
―
Senores Pharmaceuticals Ltd.
―